Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PARVB encodes a member of the parvin family of actin-binding proteins, which play a role in cytoskeleton organization and cell adhesion. Additionally we are shipping Parvin, beta Proteins (4) and many more products for this protein.
Showing 10 out of 32 products:
Human Monoclonal PARVB Primary Antibody for ELISA, WB - ABIN565418
Wu, Ng, Chen, Chang, Chuang, Weng, Liao, Pang: Expression of parvin-beta is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract. in British journal of cancer 2010
Show all 2 references for ABIN565418
Chicken Polyclonal PARVB Primary Antibody for WB - ABIN2782433
Johnstone, Mongroo, Rich, Schupp, Bowser, Delemos, Tobias, Liu, Hannigan, Rustgi: Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation. in Molecular and cellular biology 2008
Protein expression of beta-Parvin increases with colorectal cancer progression.
Taken together, our results indicate that 24-MCF treatment increases parvin-beta expression, which may inhibit ILK (show ILK Antibodies) downstream signaling.
study found polymorphisms of rs5764455 and rs6006473 in PARVB gene in the Han Chinese population, and these polymorphisms were associated with the occurrence and progression of NAFLD (show TSC2 Antibodies).
Our results suggested that variations, including insertion/deletions, in PARVB, as well as those in PNPLA3 (show PNPLA3 Antibodies), are important in the progression of NAFLD (show TSC2 Antibodies).
PARVB overexpression is a candidate biomarker for endophytic tumours and metastasis.
PARVB plays a potential role in the pathogenesis of coronary restenosis.
Polymorphisms in the SAMM50 (show SAMM50 Antibodies) and PARVB genes in addition to those in the PNPLA3 (show PNPLA3 Antibodies) gene were observed to be associated with the development and progression of NAFLD (show TSC2 Antibodies).
alpha-parvin (show PARVA Antibodies), beta-parvin and migfilin (show FBLIM1 Antibodies) were expressed in tumor cells in 53%, 2%, 28% and 53% of effusions and 57%, 20%, 83% and 25% of solid lesions, respectively.
proper localization of beta-parvin to focal adhesions requires both the paxillin (show PXN Antibodies) and integrin-linked kinase (show ILK Antibodies) binding sites and that paxillin (show PXN Antibodies) is important for early targeting of beta-parvin.
Data from functional molecular imaging demonstrated that beta-parvin plays a regulatory role in the ILK (show ILK Antibodies)-mediated Akt (show AKT1 Antibodies) (also called protein kinase B (show AKT1 Antibodies)) signaling cascades, suggesting that beta-parvin might be a crucial modulator of cell survival.
Data show that affixin is a dysferlin (show DYSF Antibodies) binding protein that colocalizes with dysferlin (show DYSF Antibodies) at the sarcolemma of normal skeletal muscle.
This gene encodes a member of the parvin family of actin-binding proteins, which play a role in cytoskeleton organization and cell adhesion. These proteins are associated with focal contacts and contain calponin homology domains that bind to actin filaments. This family member binds to alphaPIX and alpha-actinin, and it can inhibit the activity of integrin-linked kinase. This protein also functions in tumor suppression. Alternative splicing of this gene results in multiple transcript variants.